These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36212478)

  • 1. Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study.
    Bieri U; Enderlin D; Buser L; Wettstein MS; Eberli D; Moch H; Hermanns T; Poyet C
    Front Oncol; 2022; 12():964672. PubMed ID: 36212478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.
    Bieri U; Buser L; Wettstein MS; Eberli D; Saba K; Moch H; Hermanns T; Poyet C
    Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer.
    Quhal F; Pradere B; Laukhtina E; Sari Motlagh R; Mostafaei H; Mori K; Schuettfort VM; Karakiewicz PI; Rouprêt M; Enikeev D; Rink M; Abufaraj M; Shariat SF
    World J Urol; 2021 Sep; 39(9):3345-3352. PubMed ID: 33496841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Outcomes of Primary Versus Recurrent High-risk Non-muscle-invasive and Primary Versus Secondary Muscle-invasive Bladder Cancer After Radical Cystectomy: Results from a Retrospective Multicenter Study.
    Grossmann NC; Rajwa P; Quhal F; König F; Mostafaei H; Laukhtina E; Mori K; Katayama S; Motlagh RS; Fankhauser CD; Mattei A; Moschini M; Chlosta P; van Rhijn BWG; Teoh JYC; Compérat E; Babjuk M; Abufaraj M; Karakiewicz PI; Shariat SF; Pradere B
    Eur Urol Open Sci; 2022 May; 39():14-21. PubMed ID: 35528782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
    Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
    Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
    Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
    Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer.
    Mlecnik B; Bifulco C; Bindea G; Marliot F; Lugli A; Lee JJ; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Lafontaine L; Bruni D; Lanzi A; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Paustian C; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Muşină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Fox BA; Pagès F; Galon J
    J Clin Oncol; 2020 Nov; 38(31):3638-3651. PubMed ID: 32897827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of adjuvant intravesical therapies using the European Organization for Research and Treatment of Cancer scoring system in patients at intermediate risk of non-muscle-invasive bladder cancer.
    Ofude M; Kitagawa Y; Yaegashi H; Izumi K; Ueno S; Kadono Y; Konaka H; Mizokami A; Namiki M
    J Cancer Res Clin Oncol; 2015 Jan; 141(1):161-8. PubMed ID: 25108407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a New Recurrence-Free Survival Prediction Nomogram for Patients with Primary Non-Muscle-Invasive Bladder Cancer Based on Preoperative Controlling Nutritional Status Score.
    Zhao L; Sun J; Wang K; Tai S; Hua R; Yu Y; Fan Y; Huang J
    Cancer Manag Res; 2021; 13():6473-6487. PubMed ID: 34429654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma.
    Krpina K; Babarović E; Jonjić N
    Virchows Arch; 2015 Oct; 467(4):443-8. PubMed ID: 26215559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population.
    Wang Z; Gao W; Li J; Wang T; Zhu M; Duan Y
    J Cancer; 2020; 11(7):1668-1678. PubMed ID: 32194779
    [No Abstract]   [Full Text] [Related]  

  • 15. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer.
    Getzler I; Bahouth Z; Nativ O; Rubinstein J; Halachmi S
    BMC Urol; 2018 Oct; 18(1):90. PubMed ID: 30348146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification.
    Kohada Y; Hayashi T; Hsi RS; Yukihiro K; Sentani K; Goto K; Inoue S; Ohara S; Teishima J; Kajiwara M; Nishisaka T; Yasui W; Black PC; Matsubara A
    BJU Int; 2021 Apr; 127(4):473-485. PubMed ID: 32805763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology.
    Zeng L; Li SH; Xu SY; Chen K; Qin LJ; Liu XY; Wang F; Fu S; Deng L; Wang FH; Miao L; Li L; Liu N; Wang R; Wang HY
    Front Immunol; 2022; 13():878457. PubMed ID: 35619699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.